Fate Historical Financial Ratios
| FATE Stock | USD 3.17 0.49 18.28% |
Fate Therapeutics is recently reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 0.95 or Days Sales Outstanding of 9.97 will help investors to properly organize and evaluate Fate Therapeutics financial condition quickly.
Fate |
About Fate Financial Ratios Analysis
Fate TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Fate Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Fate financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Fate Therapeutics history.
Fate Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Fate Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Fate Therapeutics sales, a figure that is much harder to manipulate than other Fate Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Roic
Return on Invested Capital, a profitability ratio that measures the return that an investment generates for those who have provided capital, such as debt holders and equity holders.Most ratios from Fate Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Fate Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.At present, Fate Therapeutics' Days Of Inventory On Hand is projected to increase slightly based on the last few years of reporting. The current year's Income Quality is expected to grow to 0.84, whereas PTB Ratio is forecasted to decline to 0.95.
| 2021 | 2023 | 2024 (projected) | Payables Turnover | 0.68 | 34.26 | 18.94 | Days Of Inventory On Hand | 2.7E-5 | 2.4E-5 | 2.5E-5 |
Fate Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Fate Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fate Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 124.95 | 238.32 | 99.27 | 10.15 | 5.79 | 5.5 | |
| Ptb Ratio | 5.45 | 19.49 | 8.17 | 2.02 | 1.0 | 0.95 | |
| Book Value Per Share | 3.59 | 4.67 | 7.16 | 5.0 | 3.74 | 1.9 | |
| Free Cash Flow Yield | (0.0568) | (0.0679) | (0.005895) | (0.0385) | (0.29) | (0.36) | |
| Operating Cash Flow Per Share | (1.22) | (0.48) | (1.72) | (2.56) | (1.34) | (1.41) | |
| Stock Based Compensation To Revenue | 1.33 | 1.63 | 0.98 | 0.97 | 0.82 | 0.68 | |
| Capex To Depreciation | 3.37 | 1.6 | 8.67 | 2.59 | 0.34 | 0.32 | |
| Pb Ratio | 5.45 | 19.49 | 8.17 | 2.02 | 1.0 | 0.95 | |
| Ev To Sales | 118.13 | 236.09 | 98.93 | 10.64 | 6.76 | 6.43 | |
| Free Cash Flow Per Share | (1.33) | (0.54) | (2.25) | (2.93) | (1.41) | (1.48) | |
| Roic | (0.41) | (0.32) | (0.31) | (0.57) | (0.51) | (0.53) | |
| Net Income Per Share | (1.43) | (2.07) | (2.18) | (2.63) | (1.64) | (1.72) | |
| Payables Turnover | 15.08 | 19.99 | 0.68 | 1.66 | 34.26 | 18.94 | |
| Sales General And Administrative To Revenue | 2.21 | 1.08 | 1.03 | 0.87 | 1.28 | 1.22 | |
| Research And Ddevelopement To Revenue | 8.22 | 4.0 | 3.86 | 3.33 | 2.72 | 2.58 | |
| Capex To Revenue | 0.69 | 0.16 | 0.91 | 0.37 | 0.0968 | 0.092 | |
| Cash Per Share | 3.25 | 5.86 | 6.5 | 4.51 | 3.2 | 2.96 | |
| Pocfratio | (16.04) | (190.96) | (34.04) | (3.94) | (2.78) | (2.92) | |
| Interest Coverage | (33.22) | (39.56) | (57.49) | (52.79) | (47.51) | (49.88) | |
| Capex To Operating Cash Flow | (0.0889) | (0.13) | (0.31) | (0.14) | (0.0465) | (0.0488) | |
| Pfcf Ratio | (14.73) | (169.64) | (25.96) | (3.44) | (2.66) | (2.79) | |
| Days Payables Outstanding | 24.21 | 18.26 | 537.33 | 219.27 | 10.65 | 10.12 | |
| Income Quality | 0.85 | 0.23 | 0.77 | 0.88 | 0.82 | 0.84 | |
| Roe | (0.56) | (0.42) | (0.4) | (0.44) | (0.3) | (0.53) | |
| Ev To Operating Cash Flow | (15.17) | (189.18) | (33.92) | (4.13) | (3.25) | (3.41) | |
| Pe Ratio | (13.66) | (43.99) | (26.87) | (3.83) | (2.29) | (2.4) | |
| Return On Tangible Assets | (0.31) | (0.32) | (0.27) | (0.22) | (0.36) | (0.33) | |
| Ev To Free Cash Flow | (13.93) | (168.05) | (25.87) | (3.61) | (3.1) | (3.26) | |
| Earnings Yield | (0.0924) | (0.0732) | (0.0227) | (0.0372) | (0.26) | (0.44) | |
| Net Debt To E B I T D A | 0.77 | 0.56 | 0.0889 | (0.16) | (0.36) | (0.34) | |
| Current Ratio | 8.17 | 5.78 | 7.79 | 4.4 | 8.48 | 5.48 | |
| Tangible Book Value Per Share | 3.59 | 4.67 | 7.16 | 5.0 | 3.74 | 1.9 | |
| Graham Number | 10.76 | 14.73 | 18.74 | 17.21 | 11.74 | 10.04 | |
| Shareholders Equity Per Share | 3.59 | 4.67 | 7.16 | 5.0 | 3.74 | 1.9 | |
| Debt To Equity | 0.006913 | 0.008727 | 0.008216 | 0.0116 | 0.0168 | 0.0159 | |
| Capex Per Share | 0.11 | 0.0599 | 0.54 | 0.37 | 0.0625 | 0.088 | |
| Graham Net Net | 2.4 | 3.02 | 4.01 | 2.51 | 1.82 | 1.19 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fate Therapeutics is a strong investment it is important to analyze Fate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fate Therapeutics' future performance. For an informed investment choice regarding Fate Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share 0.123 | Quarterly Revenue Growth 0.581 | Return On Assets (0.22) | Return On Equity (0.47) |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.